HOME >> BIOLOGY >> NEWS
Gene variation affects tamoxifen's benefit for breast cancer

One of the most commonly prescribed drugs for breast cancer, tamoxifen, may not be as effective for women who inherit a common genetic variation, according to researchers at the University of Michigan and the Mayo Clinic. The genetic variation affects the level of a crucial enzyme that activates tamoxifen to fight breast cancer.

The study, co-led by researcher James Rae, Ph.D., at the University of Michigan Comprehensive Cancer Center and Matthew Goetz, M.D., an oncologist at the Mayo Clinic, tested the most common genetic variant responsible for lowering the CYP2D6 enzyme, and found that women with this genetic variant were almost twice as likely to see their breast cancer return. Up to 10 percent of women inherit this genetic trait.

Their findings are published in the Dec. 20 issue of The Journal of Clinical Oncology.

"Our group has shown that CYP2D6 is responsible for activating tamoxifen to a metabolite called endoxifen that is nearly 100 times more potent as an anti-estrogen than tamoxifen itself," says Rae, research assistant professor of internal medicine at the U-M Medical School. "Our study suggests that women who inherit a genetic variant in the CYP2D6 gene appear to be at higher risk of relapse when treated with five years of tamoxifen."

Researchers at the U-M Comprehensive Cancer Center were among the group to discover CYP2D6 metabolizes tamoxifen, and they are leading ongoing work looking at how genetic differences affect women's response to tamoxifen. Their research has also found the antidepressant drug Paxil can prevent tamoxifen from being activated, while the antidepressant drug Effexor does not. These drugs, selective serotonin reuptake inhibitors or SSRI's, are often used to treat hot flashes, a common side effect of tamoxifen.

In this current study of 256 women with breast cancer, researchers also found that women with the CYP2D6 variant were less likely to have hot flashes. Any hot flashes among this grou
'"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
16-Dec-2005


Page: 1 2

Related biology news :

1. Genetic variation helps to understand predisposition to schizophrenia
2. Success or failure of antidepressant citalopram predicted by gene variation
3. Gene variations directly link inflammation to an increased risk for lung cancer
4. Fever after smallpox vaccination tied to individual genetic variations
5. Cataloging the structural variations in human genetics
6. Common genetic variation is linked to substantial risk for heart attack
7. Study fails to verify gene variations as risk factors for certain cardiovascular problems
8. Sequence variation in the alpha synuclein gene contributes to alcohol craving
9. Vitamin D, variations in its receptor and prostate cancer
10. In Hispanic women, genetic variations linked to spontaneous preterm birth
11. Study reveals value of schizophrenia-related gene variation

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, a fast-growing ... that Eric Chen and Jessica Wong have joined the company’s leadership team as ... , Eric Chen heads development efforts for Alucio’s flagship product, Beacon, an innovative ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin ... portfolio with a near term focus on Type 2 diabetes and associated comorbidities. ... across multiple therapeutic areas and classes. As Chief Commercial Officer, Justin will lead ...
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced the first in a ... the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles ... on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... Slone Partners , ... announced the placement of Julianne Averill , CPA, as Chief Financial Officer ... operations and implementing key business strategies to accelerate Alveo’s growth as the company ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... available for free its new white paper – Simulated Transport Methodologies. Regulatory ... today’s biologics licensing application (BLA). In response, Modality Solutions shares an explanation ...
(Date:7/31/2020)... ... 2020 , ... R3 Stem Cell International is now offering patients the opportunity ... cells total, patients may choose which extremities they would like treated. , Several studies ... Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with ...
(Date:7/31/2020)... ... 29, 2020 , ... eSource has long been touted as the solution to ... of eSource, the reasons it did not take off as quickly as people initially ... industry is moving towards capturing data electronically for clinical trials and then repurposing it ...
Breaking Biology Technology:
Cached News: